

Contents

Preface.....	v
 Part I Biomarkers: Role in the Design and Interpretation of Clinical Trials	
 The Role and Potential of Surrogate Outcomes in Clinical Trials: Have We Made Any Progress in the Past Decade?	3
David L. DeMets	
 On the Use of Biomarkers to Elucidate Clinical Trial Results: Examples from the Women’s Health Initiative	21
Ross L. Prentice and Shanshan Zhao	
 On the Use of Biomarkers in Vaccine Research and Development	35
Steven G. Self	
 Part II Biomarkers: Issues in Individualized Therapy	
 Recent Developments in the Use of Clinical Trials to Support Individualizing Therapies: A Regulatory Perspective	49
Robert T. O’Neill	
 Oncology Clinical Trials in the Genomic Era	63
Richard Simon and Jyothi Subramanian	
 Using SNPs to Characterize Genetic Effects in Clinical Trials.....	81
B.S. Weir	
 Part III Issues in Multi-Regional Clinical Trials	
 Why Is This Subgroup Different from All Other Subgroups? Thoughts on Regional Differences in Randomized Clinical Trials	95
Janet Wittes	

Part IV Safety

Quantitative Risk/Benefit Assessment: Where Are We?	119
Christy Chuang-Stein	

Identifying and Addressing Safety Signals in Clinical Trials: Some Issues and Challenges	137
Thomas R. Fleming	

Past, Present, and Future of Drug Safety Assessment	157
Robert Temple	

Part V Special Topics

Designing, Monitoring, and Analyzing Group Sequential Clinical Trials Using the RCTdesign Package for R	177
Daniel L. Gillen and Scott S. Emerson	

Genetic Markers in Clinical Trials	209
B.S. Weir and P.J. Heagerty	

Addresses for Contact Authors (in the same order as the papers).....	247
---	------------

<http://www.springer.com/978-1-4614-5244-7>

Proceedings of the Fourth Seattle Symposium in

Biostatistics: Clinical Trials

Fleming, Th.R.; Weir, B.S. (Eds.)

2013, VIII, 249 p. 29 illus., 13 illus. in color., Softcover

ISBN: 978-1-4614-5244-7